Sysmex America, Inc., a leader in diagnostic solutions across hematology, hemostasis, urinalysis, flow cytometry, and informatics, has announced that it has received Health Canada approval for its CN-Series automated blood coagulation analyzers, including the Sysmex CN-3000™ and CN-6000™ systems.
These high-performance analyzers are designed to deliver timely and accurate hemostasis testing, which is vital for diagnosing patients with bleeding or clotting disorders. The approval marks a significant step in expanding access to advanced hemostasis solutions in Canada.
“The CN-Series was developed to address the evolving needs of clinical laboratories,” said Dan Zortman, CEO of Sysmex America. “With smart workflow enhancements and a compact design, these analyzers help improve efficiency, accuracy, and patient outcomes—while also supporting laboratories facing workforce shortages and increasing demand.”
The Sysmex CN-Series offers high-throughput, fully automated coagulation testing, and can be tailored to meet the specific demands of both mid-sized and high-volume laboratories. For labs managing larger workloads, an optional extended sample loader is available to increase throughput and streamline operations.
With this regulatory milestone, Sysmex continues to reinforce its commitment to providing innovative, scalable, and reliable diagnostic solutions that enhance laboratory performance and healthcare delivery.